

PHARMACY PRE-AUTHORIZATION CRITERIA



DRUG (S)	Trelegy Ellipta (fluticasone furoate/umeclidinium bromide/vilanterol trifenate)
POLICY #	11141
INDICATIONS	Trelegy Ellipta is indicated for the treatment of Chronic obstructive pulmonary disease (COPD)
CRITERIA	<p>ConnectiCare, Inc. considers Trelegy Ellipta to be medically necessary for the treatment of COPD in patients who meet the following criteria:</p> <ul style="list-style-type: none">A. Patient has a diagnosis of COPD; ANDB. Patient is 18 years of age or older; ANDC. Patient is currently well controlled on Breo Ellipta (fluticasone furoate/vilanterol trifenate) and Spiriva (tiotropium) for at least 3 months
LIMITATIONS	<p><u>Exclusion Criteria:</u></p> <ul style="list-style-type: none">1. Treatment of asthma2. Treatment of acute bronchospasm3. Hypersensitivity to milk proteins
REFERENCES	<p><u>References:</u></p> <ul style="list-style-type: none">1. Trelegy Ellipta [package insert]. Research Triangle Park, NC; GlaxoSmithKline; September 2017.2. Trelegy Ellipta Micromedex Solutions. Truven Health Analytics, Inc. Ann Arbor, MI. Available at: http://www.micromedexsolutions.com. Accessed January 8, 2018.3. Global Strategy for the Diagnosis, Management and Prevention of COPD, Global Initiative for Chronic Obstructive Lung Disease (GOLD) Updated 2017. Available at: http://goldcopd.org/gold-2017-global-strategy-diagnosis-management-prevention-copd/. Accessed December 21, 2017.
P&T REVIEW HISTORY	1/18
REVISION	1/18

PHARMACY PRE-AUTHORIZATION CRITERIA



DRUG (S)	Trelegy Ellipta (fluticasone furoate/umeclidinium bromide/vilanterol trifenate)
RECORD	